Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors
NCT07114939Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]FluorThanatrace in Pancreatic neuroendocrine tumor (PanNET), sponsored by Abramson Cancer Center. Primary endpoint: [18F]FTT SUV in PanNETS. Started Oct 2025; status: recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT07114939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114939.